Skip to main content

A person wearing a face mask walks along Wall Street on March 6.

Andrew Kelly/Reuters

As U.S. companies gear up for what may be the gloomiest reporting period since the financial crisis, the consumer staples, health care and technology sectors could be comparative bright spots.

Most sectors are expected to bring dire news this earnings season in the wake of the U.S. coronavirus outbreak, which has produced the most cases of any country. Economists widely expect a severe economic downturn as a result.

Given the outbreak is expected to have hampered a broad swath of the economy in the first quarter, analysts are forecasting an 8.1-per-cent drop in earnings from the previous year, down from estimated profit growth of 6.3 per cent at the start of the year, according to IBES data from Refinitiv. That would be the biggest earnings decline since the third quarter of 2009, when profits fell 14.7 per cent from a year earlier.

Story continues below advertisement

Moreover, a number of companies have pulled guidance for the quarter, raising worries that analysts’ forecasts for the period may underestimate the extent of the fallout from the virus.

The energy, consumer discretionary and industrials sectors have been cited for the biggest declines in forecasts since Jan. 1, and investors have been bracing for especially poor results from travel, entertainment, energy and discretionary companies in general.

The S&P Composite 1500 airlines index, for instance, remains down 51.8 per cent since Feb. 19, when the benchmark S&P 500 ended its nearly 11-year bull market and coronavirus fears sparked a deep sell-off on Wall Street. The S&P 500 is down 17.6 per cent since that date.

Estimates for technology, communication services, health care, consumer staples and utilities have fallen as well, but all of those sectors still are expected to post some profit gains for the quarter, based on Refinitiv’s data.

Analysts see quarterly earnings in the technology sector up 2.6 per cent from 2019, communication services up 7.8 per cent, utilities up 2.3 per cent, health care up 1.6 per cent and consumer staples up 0.9 per cent.

Technology’s relatively high cash balances and lower debt make it “a rare cyclical safe haven,” said Daniel Morgan, vice-president and senior portfolio manager at Synovus Trust Company in Atlanta.

That is due in part to software spending, which has been resilient, said Mr. Morgan, who lists Microsoft, Nvidia and Citrix Systems among his top 10 picks of stocks likely to hold up better than others this earnings season.

Story continues below advertisement

“You’re going to continue to see companies trying to streamline to become more productive. That trend to me is still intact,” he said.

Mr. Morgan also likes stocks in health care like Regeneron Pharmaceuticals and in staples, such as Clorox Co. .

The rush to stock up on household items like toilet paper and cleaning materials has driven up shares of staples companies since the outbreak, which began in China late last year and then spread through Europe and the United States.

“Kimberly-Clark is the one that leaps to mind,” said Kim Forrest, chief investment officer at Bokeh Capital Partners in Pittsburgh, referring to companies that have held up. Shares of Kimberly-Clark Corp surged following the outbreak but are down 8.5 per cent since Feb. 19.

To be sure, some companies whose shares have outperformed may end up reporting lackluster reports. That is especially a hazard for grocery chains, according to Ms. Forrest. “The stuff that people are snapping up is the low-margin stuff. Revenues will be higher, but Wall Street likes earnings,” she said.

Shares of Gilead Sciences and Regeneron, which are developing potential treatments for COVID-19, the disease caused by the novel coronavirus, have performed particularly well.

Story continues below advertisement

The S&P 500 health care index is down less than 9 per cent since Feb. 19.

Next week brings results from JPMorgan Chase and other big banks, but also from some names in health care, including Johnson & Johnson and Intuitive Surgical , while reports are due from International Business Machines and Procter & Gamble the following week.

Goldman Sachs strategists, who are expecting a 15 per cent year-over-year decline in first-quarter S&P 500 earnings and a 33-per-cent decline in 2020 earnings, wrote that they expect profits in defensive sectors such as consumer staples, health care and utilities to be insulated relative to most cyclical sectors.

In addition, they said, “we expect Info Tech EPS will fall by less than the broad index in 2020, given the high share of recurring revenues for some of the largest stocks.”

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Coronavirus information
Coronavirus information
The Zero Canada Project provides resources to help you manage your health, your finances and your family life as Canada reopens.
Visit the hub

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies